MMJ BioPharma Cultivation
MMJ BioPharma Cultivation, is the premier US medical cannabis cultivation and research company. MMJ BioPharma Cultivations’ mission is rooted in unlocking the potential of cannabinoid medicines to address serious medical conditions with limited treatment options. Our efforts are guided by several fundamental principles. At all times we strive to be:
- Patient Driven – patients motivate everything we do
- Passionate – we are here to change lives
- Innovative – we challenge ourselves to find new and better medicines
- Collaborative – we accomplish more through working together
- Accountable – we take responsibility and deliver on our commitments
- Integrity – we are fair, honest, and ethical
- Excellence – we strive to work to the highest FDA, DEA standards
In living these values, we believe we can fulfill our mission to be the United States leader in the cultivation of prescription cannabinoid medicines, developing and providing pharmaceutical products which address patients clear unmet medical needs. Under the 1961 international Single Convention on Narcotic Drugs and the 1970 Controlled Substances Act, the federal government is the single “agent” allowed to provide marijuana for research. As of now, the DEA has only authorized one grower. However, in 2016 the DEA announced a new interpretation of the Single Convention to allow other growers to cultivate marijuana to supply researchers.
MMJ BioPharma Cultivation has applied for a DEA Schedule-I Bulk Manufacturer registration to cultivate plants for this purpose. MMJ BioPharma Cultivation will facilitate a process of scientific drug development and discovery governed by FDA protocol development processes, intellectual property portfolio and DEA regulatory manufacturing guidelines.
Once approved by the DEA, MMJ BioPharma Cultivation will one of the first harvesters of cannabis plants to conduct a unique pharmaceutical research and development program into the medicinal uses of cannabis. Sowing will commence as soon as permitted, and the initial crop of 5,000 plants will be grown in a climate controlled building at a secure research facility on an undisclosed Indian Tribal location.
Eventually, as many as 20,000 plants should be under cultivation. Dr. Elio Mariani stated ”The plants we will be harvesting will be used as prototype plant genetics for further extraction, studies and formulations, as well as in any FDA approved clinical trials. By the end of 2020, we intend to be working with pharmaceutical grade extracts from cloned plants, rather than growing from seed. We will then be growing and harvesting on a regular basis for supply to approved Clinical trials. We will be using whole plant extracts for clinical trials by multiple delivery methods to perfect a more precise and controllable delivery dose.
MMJ BioPharma Cultivation has executed a Memorandum of Understanding with a pharmaceutical development company with the first area of clinical trials supply to patients for the relief of nerve damage pain including for sufferers of MS (multiple sclerosis) and HD (huntington’s disease).”